Skip to content

Study · Systematic review · 2026

7 results

Efficacy and Safety of Oral GLP-1 RA Orforglipron on Weight and Glycemic Control According to Diabetes Status: A Systematic Review and Meta-Analysis.

Hammad N, Ramadan AM, Nazmy A, Elazab A, Abdelaziz A

Diabetes technology & therapeutics4 Feb 2026Cited by 2 (Europe PMC)

PMID41640110 (opens in a new tab)DOI10.1177/15209156261420404 (opens in a new tab)PepBankPUB-41640110
Publisher pagePubMedAsk about this study
Jump to 7 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study7

7 results from studies that gave the peptide. 7 results from people.

  1. 01HumanSystematic reviewEfficacy outcome

    In obese adults with diabetes, orforglipron reduced body weight dose-dependently, with losses exceeding 6 kg at 36 mg.

    In plain wordsIn obese adults with diabetes, orforglipron reduced body weight more at higher doses.

    Peptide
    Orforglipron
    Outcome
    DecreaseBody weight with diabetes
    Study

    n: not reported in source

    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    3-36 mg once daily · oralAs given in this study (human).

    Measurements

    Body weight loss
    > 6 kg
    36 mg, patients with diabetes

    Source sentences

    Summary
    Orforglipron produced consistent, dose-dependent reductions in body weight, ranging from modest losses at 3 mg to more than 6 kg at 36 mg in patients with diabetes.
    2 context sentences
    Summary · context
    This meta-analysis aimed to evaluate the efficacy and safety of once-daily oral orforglipron in obese adults with and without diabetes.
    Summary · context
    Five randomized controlled trials (n = 6140) were included.
  2. 02HumanSystematic reviewEfficacy outcome

    In obese adults without diabetes, orforglipron weight reductions approached 12 kg at the highest dose and exceeded those with diabetes.

    In plain wordsIn obese adults without diabetes, orforglipron weight loss was greater than in adults with diabetes.

    Peptide
    Orforglipron
    Outcome
    DecreaseBody weight without diabetes
    Study

    n: not reported in source

    Comparator
    Adults with diabetes
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated · oralAs given in this study (human).

    Measurements

    Body weight loss
    ≈ 12 kg
    highest dose, patients without diabetes

    Source sentences

    Summary
    Individuals without diabetes experienced greater weight reductions, approaching 12 kg at the highest dose.
    3 context sentences
    Summary · context
    Orforglipron produced consistent, dose-dependent reductions in body weight, ranging from modest losses at 3 mg to more than 6 kg at 36 mg in patients with diabetes.
    Summary · context
    This meta-analysis aimed to evaluate the efficacy and safety of once-daily oral orforglipron in obese adults with and without diabetes.
    Summary · context
    Five randomized controlled trials (n = 6140) were included.
  3. 03HumanSystematic reviewEfficacy outcome

    In obese adults, orforglipron significantly improved body mass index.

    In plain wordsIn obese adults, orforglipron improved body mass index.

    Peptide
    Orforglipron
    Outcome
    DecreaseBody mass index
    Study

    n: not reported in source

    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated · oralAs given in this study (human).

    Source sentences

    Summary
    Significant improvements in body mass index, waist circumference, and glycated hemoglobin (HbA1c; -1.29%) were also observed.
    2 context sentences
    Summary · context
    This meta-analysis aimed to evaluate the efficacy and safety of once-daily oral orforglipron in obese adults with and without diabetes.
    Summary · context
    Five randomized controlled trials (n = 6140) were included.
  4. 04HumanSystematic reviewEfficacy outcome

    In obese adults, orforglipron significantly improved waist circumference.

    In plain wordsIn obese adults, orforglipron improved waist circumference.

    Peptide
    Orforglipron
    Outcome
    DecreaseWaist circumference
    Study

    n: not reported in source

    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated · oralAs given in this study (human).

    Source sentences

    Summary
    Significant improvements in body mass index, waist circumference, and glycated hemoglobin (HbA1c; -1.29%) were also observed.
    2 context sentences
    Summary · context
    This meta-analysis aimed to evaluate the efficacy and safety of once-daily oral orforglipron in obese adults with and without diabetes.
    Summary · context
    Five randomized controlled trials (n = 6140) were included.
  5. 05HumanSystematic reviewEfficacy outcome

    In obese adults, orforglipron lowered HbA1c, with a reported change of -1.29%.

    In plain wordsIn obese adults, orforglipron lowered HbA1c, which tracks long-term blood sugar.

    Peptide
    Orforglipron
    Outcome
    DecreaseHbA1c
    Study

    n: not reported in source

    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · oralAs given in this study (human).

    Measurements

    HbA1c change
    −1.29%
    orforglipron

    Source sentences

    Summary
    Significant improvements in body mass index, waist circumference, and glycated hemoglobin (HbA1c; -1.29%) were also observed.
    2 context sentences
    Summary · context
    This meta-analysis aimed to evaluate the efficacy and safety of once-daily oral orforglipron in obese adults with and without diabetes.
    Summary · context
    Five randomized controlled trials (n = 6140) were included.
  6. 06HumanSystematic reviewSafety outcome

    In obese adults, gastrointestinal adverse events increased with higher orforglipron doses.

    In plain wordsIn obese adults, higher orforglipron doses increased gut-related adverse events.

    Peptide
    Orforglipron
    Outcome
    IncreaseGastrointestinal adverse events
    Study

    n: not reported in source

    Comparator
    Lower doses
    Outcome group
    Gastrointestinal adverse events · Gastrointestinal
    Studied dose
    Dose not stated · oralAs given in this study (human).

    Source sentences

    Summary
    Gastrointestinal adverse events increased with higher dose, and no significant difference in the incidence of acute pancreatitis was identified.
    2 context sentences
    Summary · context
    This meta-analysis aimed to evaluate the efficacy and safety of once-daily oral orforglipron in obese adults with and without diabetes.
    Summary · context
    Five randomized controlled trials (n = 6140) were included.
  7. 07HumanSystematic reviewSafety outcome

    In obese adults, orforglipron showed no significant difference in acute pancreatitis incidence.

    In plain wordsIn obese adults, acute pancreatitis incidence did not differ significantly with orforglipron.

    Peptide
    Orforglipron
    Outcome
    No significant changeAcute pancreatitis
    Study

    n: not reported in source

    Outcome group
    Adverse events · Gastrointestinal
    Studied dose
    Dose not stated · oralAs given in this study (human).

    Source sentences

    Summary
    Gastrointestinal adverse events increased with higher dose, and no significant difference in the incidence of acute pancreatitis was identified.
    2 context sentences
    Summary · context
    This meta-analysis aimed to evaluate the efficacy and safety of once-daily oral orforglipron in obese adults with and without diabetes.
    Summary · context
    Five randomized controlled trials (n = 6140) were included.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    14 Oct 2026, 05:02 UTC

    Study results updated

  2. Version 1

    14 Oct 2026, 01:46 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.